Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](INSYS Therapeutics Inc)"
Count: 49
Selected: 0
NCT IDTitle
NCT03827642A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy Volunteers
NCT03827629A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers
NCT03254459Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain
NCT02915978Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain
NCT02641340Fentanyl Sublingual Spray in Opioid Naive Participants
NCT02634788Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain
NCT02604992Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers
NCT02576353Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects
NCT02551731Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms
NCT02477267Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers
NCT02324673Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders
NCT02318602Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
NCT02318563Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome
NCT02318537Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
NCT02310581Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain
NCT02138409Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting
NCT02138396Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions
NCT02137525Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain
NCT02094599A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users
NCT01832974Possible New Therapy for Advanced Cancer
NCT01780233Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)
NCT01448772Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions
NCT01190982Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer
NCT01188408Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
NCT01186731Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer
NCT01151384Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors
NCT00956254Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis
NCT00538863Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain
NCT00538850Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
NCT00378235Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
NCT00100672Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer
NCT00100139Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer
NCT00089427IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
NCT00080418Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
NCT00076986The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
NCT00064779Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
NCT00046540Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer
NCT00041587Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
NCT00024687Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
NCT00024674Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days
NCT00024661Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors
NCT00024648Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies
NCT00024570Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
NCT00024557Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
NCT00024492Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer
NCT02902081Cannabidiol and Emotional Stimuli
NCT02751359Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers
NCT02597478Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea
NCT02514252Sublingual Fentanyl for the Management of Breakthrough Pain